The annual event brings together basic scientists, clinical researchers, early career investigators, clinicians and the care research community to discuss the latest developments and innovation in Alzheimer’s and dementia research.
With only a fifth of WHO Member States meeting their commitments to the Global Action Plan on dementia, urgent action is needed to address the escalating global dementia crisis.
In this blog from Orquidea Tamayo Mortera of Summerset, one of New Zealand’s leading independent retirement village operators, Orquidea writes about how Summerset is responding and rising to the evolving challenges of care for people living with dementia through innovative ways.
The communiqué calls on the G20 to lead the way in being truly values-driven for global impact and to operate in an environment where there is an agreement on shared values, clarity on unique values across nations, understanding of the values of difference and more.
In this blog from Samantha Loi of the Australian Young Onset Dementia Special Interest Group (YOD-SIG), Samantha examines the complexities experienced by people living with young onset dementia when accessing post-diagnostic care, support and treatment.
Results from the LUCIDTY Phase 3 study suggests initial positive results for early and mild to moderate Alzheimer’s Disease
‘Integrating palliative care for older adults’ was written with ADI, The Worldwide Hospice Palliative Care Alliance (WHPCA), SANAD Hospice Lebanon and Hamad Medical Corporation (HMC).
In this exercept from the essay 'Providing optimal dementia support to Indigenous people in North America', from the World Alzheimer Report 2022, Jordan P Lewis (Aleut) and Kristen M Jacklin write about the need for culturally tailored dementia care in Indigenous communities in North America.
We asked some of our sponsors what inspires them to support World Alzheimer's Month as well as people living with dementia and their families.
ADI warmly welcomes the positive initial data reported today by Eisai and Biogen on the CLARITY AD global Phase 3 clinical trial of lecanemab.